文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

人型支原体与脲原体临床分离株对四环素类耐药性的系统综述与荟萃分析

Resistance to tetracyclines among clinical isolates of Mycoplasma hominis and Ureaplasma species: a systematic review and meta-analysis.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

该研究系统检索多个数据库并纳入37项来自不同国家的研究,对生殖支原体属中人型支原体与脲原体属(解脲脲原体/微小脲原体)临床分离株对四环素、多西环素和米诺环素的耐药率进行荟萃分析。结果显示总体耐药率相对较高且在全球流行,提示治疗前应开展区域性药敏检测并研发新型四环素类药物。

要点

  • 人型支原体对四环素中位耐药率为50.0%,对多西环素为9.0%,对米诺环素为16.7%。
  • 解脲脲原体/微小脲原体对四环素中位耐药率为43.3%,对多西环素为28.6%,对米诺环素为9.0%。
  • 治疗选择前应进行区域和本地抗菌药物敏感性检测,并研发新一代四环素类。

核心结论

  • 全球范围内人型支原体与脲原体属对四环素类的总体耐药率相对较高且广泛流行。
  • 研究强调治疗前进行区域和本地药敏检测的必要性,并呼吁研发新一代四环素类以防止治疗失败。

研究设计与样本

  • 系统综述与荟萃分析,检索多个电子数据库后最终纳入37项来自不同国家的研究。

主要发现

  • 人型支原体对四环素、多西环素和米诺环素的中位耐药率分别为50.0%、9.0%和16.7%。
  • 解脲脲原体/微小脲原体对四环素、多西环素和米诺环素的中位耐药率分别为43.3%、28.6%和9.0%。
  • 除人型支原体多西环素耐药研究(I2=39.1%,P=0.02)外,所有研究均观察到高度异质性(I2>50%,P<0.05)。
  • Egger检验与Begg检验均未显示显著发表偏倚。

临床怎么用

  • 对泌尿生殖道支原体感染选择四环素类治疗前,应结合区域和本地药敏结果个体化决策。
  • 临床应关注人型支原体与脲原体属对多西环素、米诺环素耐药率的差异,避免经验性滥用。

局限性

  • 纳入研究间异质性普遍较高(多数I2>50%),可能影响合并耐药率的稳健性。
  • 原文摘要未报告各研究的具体人群、标本来源与药敏方法等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Resistance to tetracyclines, the first-line treatment for urogenital infections caused by Mycoplasma hominis and Ureaplasma species, is increasing worldwide. The aim of the present study was to determine the global status of resistance to this class of antibiotics. METHODS: Electronic databases were searched using keywords including 'Mycoplasma', 'Mycoplasma hominis', 'M. hominis', 'Ureaplasma', 'Ureaplasma urealyticum', 'Ureaplasma parvum', 'U. urealyticum', 'U. parvum', 'Ureaplasma species', 'resistance', 'antibiotic resistance', 'antibiotic susceptibility', 'antimicrobial resistance', 'antimicrobial susceptibility', 'tetracycline', 'doxycycline' and 'minocycline'. Finally, after some exclusions, 37 studies from different countries were included in the study and meta-analysis was performed on the data collected. RESULTS: The midrange resistance rates for M. hominis and U. urealyticum/parvum to tetracycline, doxycycline and minocycline were 50.0%, 9.0% and 16.7% and 43.3%, 28.6% and 9.0%, respectively. A high level of heterogeneity was observed in all studies (I2 > 50%, P value < 0.05), except those representing doxycycline resistance in M. hominis isolates (I2 = 39.1%, P = 0.02). No evidence of publication bias was observed in the studies and neither Egger's test nor Begg's test showed significant publication bias. CONCLUSIONS: The results of the present study show that the overall resistance to tetracyclines is relatively high and prevalent among M. hominis and Ureaplasma species throughout the world. This highlights the importance of and necessity for regional and local antibiotic susceptibility testing before treatment choice as well as development of newer generations of tetracyclines to prevent antibiotic misuse, emergence and spread of resistant strains and, finally, the failure of treatment.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Ahmadi MH. Resistance to tetracyclines among clinical isolates of Mycoplasma hominis and Ureaplasma species: a systematic review and meta-analysis. J Antimicrob Chemother. 2021. PMID: 33367765. doi:10.1093/jac/dkaa538

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。